TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Biopsy proven relapsed malignant melanoma that has failed prior standard regimen for metastatic disease Must have HLA-matched or related bone marrow donor (5- or 6-antigen match) No history of CNS metastases~PATIENT CHARACTERISTICS: Age: 16 to 44 Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Not specified Hepatic: SGOT and SGPT less than 1.5 times upper limit of normal Bilirubin less than 1.5 mg/dL Renal: Creatinine less than 1.5 mg/dL AND/OR Creatinine clearance greater than 75 mL/min Cardiovascular: No history of cardiac disease No symptomatic cardiac disease Ejection fraction greater than 50% Pulmonary: FEV1 greater than 50% predicted (greater than 75% if received thoracic irradiation) DLCO greater than 50% predicted Other: Not pregnant Fertile women must use effective contraception HIV negative No active bacterial, fungal, or viral infection Hepatitis B negative~PRIOR CONCURRENT THERAPY: At least 1 prior standard regimen for metastatic disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Each patient must meet the following criteria:~* Age 38-43 years at the time of enrollment~* Diagnosis of primary infertility~Exclusion Criteria:~* Patients must NOT have any of the following:~* Body mass index (BMI) \> 38 kg/m2~* Early follicular phase (day 2-4) serum FSH level \> 20 mIU/ml.~* Abnormal uterine cavity and /or tubal blockage as evidenced by sonohysterogram or hysterosalpingography~* Any current use of systemic steroid medication within 3 months of study enrollment.~* Any contraindication to being pregnant and carrying a pregnancy to term.~* Contraindication for the use of CoQ10, Menopur, hCG, and Prometrium.~* Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.~* Absence of one ovary~* Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal dysfunction, organic intracranial lesion, hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia).~* History (within past 12 months) or current abuse of alcohol or drugs.~* Administration of any investigational drugs within three months prior to study enrollment.~* Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes and liver dysfunction~* Unexplained gynecological bleeding.~* Abnormal sperm quality or semen sample inadequate for IUI preparation (TMC \> 1x106 post wash)~* Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.~* Abnormal COH screening bloods for either partner, including: HIV serology, Hepatitis B and C serology, Rubella, and syphilis serology prior to participation in study.~* Unwillingness to give written informed consent.~* The concurrent use of any of the following drugs:~* CoQ10: Daunorubicin, Doxorubicin, Blood Pressure Medications, Warfarin, Timolol, atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin gemfibrozil, tricyclic antidepressant medications (including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine).

- Gender: FEMALE
- Minimum Age: 38 Years
- Maximum Age: 43 Years
- Healthy Volunteers: t

Study Arms:
- CoQ10 (Type: EXPERIMENTAL): Coenzyme Q10 co-treatment
- Placebo control (Type: PLACEBO_COMPARATOR): Placebo Co-treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~I1) Male or female patient aged 18 years or over, weighing \>50 Kg and \<120 Kg, at the time of signing the informed consent,~I2) Patient presenting in a specialized or an emergency unit~I3) Patient presenting signs of pneumonia evidenced by at least 1 of the following: auscultation, chest X-Ray, CT scan OR presenting COVID-19 related symptoms having started less than 10 days prior to screening visit, including at least 2 of the following: fever, cough, sore throat or nasal discharge, dyspnea (shortness of breath), thoracic pain, headache or fatigue, myalgia, anosmia, dysgeusia, diarrhea, nausea~I4) Patient with SpO2 \> 90% (at ambient air)~I5) Patient with a first positive SARS-CoV-2 test (RT-PCR, RT-qPCR or antigen test) in the last 10 days or at screening~I6) Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at screening and use a highly effective birth control until 90 days after the administration of study drug~I7) Non-vasectomized male patients having a female partner of childbearing potential must agree to use a highly effective method of contraception until 90 days after the administration of study drug,~I8) Patient capable of giving signed informed consent.~Exclusion Criteria:~E1) Patient with a positive SARS CoV-2 test (RT-PCR, RT-qPCR or antigen test) of more than 10 days before the screening visit~E2) Patient with multiorgan failure~E3) Patient requiring immediate Intensive Care Unit (ICU) hospitalization~E4) Patient participating in another clinical trial with an investigative agent~E5) Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XAV-19 (Type: EXPERIMENTAL): XAV-19
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stroke or TIA within 30 days~* Above 50 years of age~Exclusion Criteria:~* Deceases og the esophagus~* Dementia~* Allergy to aspirin~* Risk of non-compliance~* Lacking ability to give written or oral consent~* Atrial Fibrillation~* Neurological deficit lasting less than 6 hours

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device closure of PFO (Type: EXPERIMENTAL): Device closure of PFO followed by 6 month treatment with clopidogrel 75 mg and 75 - 150 mg of aspirin daily followed by a life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
- Medical anticoagulative treatment (Type: ACTIVE_COMPARATOR): Life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perfusion Imaging and CT -Understanding Relative Efficacy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with an intermediate probability risk for coronary artery disease.~* Subject has symptoms of suspected ischemic heart disease.~* Subject is at intermediate risk for coronary artery disease~Exclusion Criteria:~* The subject has undergone a prior CCTA within 6 months prior to entering the study.~* The subject has a documented history of CAD by CATH, myocardial infarction (MI), metal stent placement in any of the coronary vessels, or a previous coronary artery bypass graft (CABG) procedure~* The subject has hemodynamic or active clinical instability:~  * Acute chest pain (sudden onset);~ * Cardiac shock;~ * Unstable blood pressure (BP);~ * Severe congestive heart failure or acute pulmonary edema.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imaging (Type: EXPERIMENTAL): General imaging subjects receiving CT exams

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a mobile phone with text message capability~* Patient of University of Maryland Medical Center outpatient gynecology clinics~* Able to speak and read English~* Capable of understanding, consenting, and complying with the entire study protocol~Exclusion Criteria:~* Pregnant~* Previously completed the Gardasil vaccine

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Participants follow the usual practices for scheduling their follow up visit(s) for vaccination at the clinic. Participants will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate).
- SMS Text Message (Type: EXPERIMENTAL): Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate). Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Shifting Pain Modulation From Pro-to Anti-nociceptive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* American society of anesthesiologists (ASA) I - III patients planned for elective herniorraphy.~Exclusion Criteria:~* Report of pain at hernia site for more than 30 on 0-100 Numeric Pain Scale (NPS) (ranging from 0, denoting ''no pain'', to 100, denoting ''the worst pain imaginable''), for most of the days during past one month.~* Regular use of analgesia for any purpose, including serotonin-norepinephrine re-uptake inhibitors (SNRIs) and gabapentins during the previous month.~* Use of monoamine oxidase inhibitors (MAOIs) within the last 14 days.~* Narrow-angle glaucoma.~* Known pregnancy or lactation.~* Chronic pain disorders.~* Inability to perform psycho-physical testing, as in the case of cognitive or psychiatric disorders. Participants will sign a consent form before recruitment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Duloxetine (Type: ACTIVE_COMPARATOR): Treatment
- Pregabalin (Type: ACTIVE_COMPARATOR): Treatment
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Collagenase With Antibiotic Ointment of Minor Partial Thickness Burns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information. For subjects not able to provide informed consent (e.g., minors), a parent or legally authorized representative must provide consent. Assent must be provided as required by the Institutional Review Board (IRB).~2. Have one or more acute burns which:~   1. are thermal, chemical or electrical in etiology~  2. in aggregate cover \<10% total body surface area (TBSA)~  3. are each equal to or less than 72 hrs old~  4. are each no more than deep partial thickness (2nd degree)~  5. are not visibly infected~3. Able to take in oral fluids.~4. Able to comply with the requirement for daily dressing changes, or have a caretaker who is able to comply.~5. Willing to make all required study visits.~Exclusion Criteria:~1. Contraindications or hypersensitivity to the use of the test article or their components (e.g., known hypersensitivity to bacitracin).~2. Embedded foreign bodies in the burn wound which cannot be immediately removed.~3. The burned tissue includes or is within 1 cm of the eye or genitalia.~4. Severe perioral burns.~5. Airway involvement or aspiration of hot liquids.~6. Suspicion of physical abuse.~7. Burn wound requires a skin graft.~8. Outpatient management of the burn wound is not appropriate.~9. Participation in another investigational clinical study within thirty (30) days of the Screening Visit.~10. The Investigator may declare any subject ineligible for a valid medical reason. Current or recent (\< 6 months) history of severe, unstable, or uncontrolled neurological, cardiovascular, gastrointestinal, hematological, hepatic, and/or renal disease or evidence of other diseases based upon a review of medical history that, in the opinion of the Investigator, would preclude safe subject participation in the study.~11. Test articles are cost-prohibitive for subjects

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Collagenase Santyl (Type: ACTIVE_COMPARATOR): Applied topically (2 mm thickness once daily)
- Bacitracin (Type: SHAM_COMPARATOR): Applied topically (2 mm thickness) once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of IPF.~* Receiving supplemental oxygen for use at rest.~* Weight ≥ 40 kg.~* Male or female of child bearing potential willing and able to use highly effective methods of contraception from study start to 30 days after the last dose of study drug.~Exclusion Criteria:~* FEV1/FVC \< 70%~* History of other interstitial lung diseases.~* Subject plans to begin or has commenced pulmonary rehabilitation within 30 days of screening.~* Corticosteroid (\> 10 mg per day of prednisone or an equivalent) administered for 7 days or longer, within 30 days of screening.~* Participated in another clinical trial of an investigational drug (or medical device) within 30 days or 5-half-lives, whichever is longer, prior to screening, or is currently participating in another trial of an investigational drug (or medical device).~* Female who is breast-feeding or pregnant~* Current smoker or history of smoking within 3 months from screening

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- GBT440 900 mg Dose (Type: EXPERIMENTAL): Part A, 900 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange
- GBT440 1500 mg Dose (Type: EXPERIMENTAL): Part B , 1500 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Standardizing Management of Patients With Low Back Pain in Primary Care and Physical Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of pain and/or numbness between the 12th rib and buttocks with or without symptoms into one or both legs, which, in the opinion of the primary care provider, originate from the lumbar region.~* Age 18 - 60 years~* Oswestry disability score \> 20%~* Both of the clinical decision rule criteria: Duration of current symptoms \< 16 days, and patient report of no symptoms (pain, numbness, etc.) distal to the knee since onset.~Exclusion Criteria:~* Prior surgery to the lumbosacral spine~* Current pregnancy~* Neurogenic LBP defined as the presence of either: a positive straight leg raise test (symptom reproduction at \<450) or reflex, sensory, or strength consistent with lumbar nerve root compression~* Judgment of the primary care provider of red flags of a potentially serious condition including cauda equina syndrome, major or rapidly progressing neurological deficit, fracture, cancer, or infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Early Treatment (Type: EXPERIMENTAL): None
- Usual Care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female ≥ 18 years, ≤70 years.~* Minimum life expectancy 16 weeks~* Histologicalconfirmation of hormone receptor negative and HER2 negative breast cancer(IHC:ER -, PR-) on primary tumour at diagnosis/on biopsy of metastasis~* Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection~* ECOG 0-2 with no deterioration over previous 2 weeks Measurable disease~* Adequate bone marrow and organ function~* Availability of archival tumour sample or fresh biopsy Informed consent~* Normal organ function~Exclusion Criteria:~* Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour embolisation \<21 days prior to study treatment~* Last dose of palliative radiotherapy \<7 days prior to study treatment~* Rapidly progressive visceral disease not suitable for further therapy~* Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and stable and not requiring steroids for ≥ 4 weeks study treatment~* Major surgery (excluding placement of vascular access) within 4 weeks before study treatment~* Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV~* With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment~* Elevated ALP in absence of bone metastasis~* Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent~* Participation in another study with investigational product during last 30 days~* Inability or unwillingness to comply with study procedures, including inability to take regular oral medication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Epalrestat (Type: EXPERIMENTAL): Epalrestat added to standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with traumatic brain injury admitted to the hospital less than 24 hours prior to randomization~* GCS score 3-8 (inclusive) or GCS motor score of 5 or less and abnormal admission CT scan showing intracranial pathology~* Hemodynamically stable with a systolic BP \> 90 mmHg~* At least one reactive pupil~* Age at least 18 years~* Signed informed consent and HIPAA authorization for research form~* Patients will not be excluded because of race, gender, educational status or occupation~Exclusion Criteria:~* No venous access~* Spinal cord injury~* History of or CT confirmation of previous brain injury such as brain tumor, cerebral infarct, or spontaneous intracerebral hemorrhage~* Hemodynamically unstable~* Suspected anoxic events~* Other peripheral trauma likely to result in liver failure~* Age less than 18 years of age~* Known hypersensitivity to any anticonvulsant~* Any treatment, condition, or injury that contraindicates treatment with Lacosamide (LCM) or fos-phenytoin (fPHT)~* Inability to obtain signed informed consent or HIPAA authorization for research

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV LCM (lacosamide) (Type: EXPERIMENTAL): Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.
- IV fPHT (fos-phenytoin) (Type: ACTIVE_COMPARATOR): Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues